bioRxiv Science⌕ Search

bioRxiv · 10.64898/2026.11.06.764971

Deep phenomics of African green monkey and Baboon PBMCs using a 30-marker spectral flow cytometry panel

Abstract

Vaccines are the best way to prevent and combat diseases. Non-human primate (NHP) models have proven to be the gold standard model for studying the efficacy of certain vaccine candidates prior to human trials. Cell-mediated immunity serves as a surrogate marker for predicting vaccine efficacy. Despite the availability of deep-immunophenotyping panels for T cells in the peripheral blood of humans, their application to NHPs, particularly African Green Monkeys (AGMs) and baboons, remains limited. Notably, AGMs are valuable for HIV and COVID-19 research, while baboons are utilized for pertussis research as a natural infection model and vaccine trial. To overcome such limitation, using spectral flow cytometry, we developed a 30-parameter panel to profile major immune cell subsets (B cells, NK cells, DCs, monocytes) either in AGM or baboon PBMCs. We also profiled T cells, memory phenotypes, functional cytokines by tracking established Th1 markers IFN{gamma}, TNF and IL-2; Th2 markers IL-4/5/13 and the Th17 marker, IL-17, activation-induced markers (AIMs) and FoxP3+ Tregs in both AGM and baboon PBMCs in steady state as well as in mitogen stimulated conditions. For AIMs, CD69, CD134 (OX40) and CD137 (4-1BB) are included and validated in both NHP species. This panel holds potential for exploratory analysis of the impact of these functional cytokines, AIMs, or Tregs on host immunity following infection or vaccination. The panels high level of customization empowers researchers to tailor it to their specific research needs.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Barman, S., Patel, A., Buonopane, M. J., Janoschek, B., Hingorani, R., Dowling, D. J.. 2026-11-09. Deep phenomics of African green monkey and Baboon PBMCs using a 30-marker spectral flow cytometry panel. https://doi.org/10.64898/2026.11.06.764971

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Ksp37 is a rapidly mobilized NK cell secretory protein that engages FGF2

A key feature of natural killer (NK) cells is their preloaded arsenal of effector molecules, allowing them to rapidly respond upon activation. In this study, we characterized a previously unexplored secretory protein, termed killer-specific secretory protein of 37 kDa (Ksp37), which is highly abundant in differentiated CD56dim NK cells. Ksp37 is rapidly secreted in a dose-dependent and JAK-1 dependent manner upon low levels of cytokine stimulation, making it a sensitive readout for NK cell activation. Following secretion, intracellular levels were rapidly replenished, preserving responsiveness to subsequent cytokine stimulation. We found that Ksp37 is stored in polarized intracellular compartments distinct from those containing canonical cytotoxic effector molecules, including granzyme B and perforin, which require stronger stimulation for release. Lastly, we identified Ksp37 as a novel binding partner of fibroblast growth factor 2 (FGF2). This opens new avenues of exploration for the role of NK cells in remodeling their extracellular environment by modulating the FGF2-FGFR1 axis, which plays a key role in tumor growth, angiogenesis and tissue repair.

immunology↗

ACE-engineered human iPSC-derived neutrophils enhance host defense against multidrug-resistant bacterial infections

Severe neutropenia predisposes patients to life-threatening infections, while donor-dependent granulocyte transfusions are limited by availability and variable cell quality. Here, we engineered human induced pluripotent stem cells (iPSCs) to constitutively or inducibly express angiotensin-converting enzyme (ACE) and differentiated them into functional ACE-engineered neutrophils (ACE-iNeu). ACE expression enhanced granulocytic maturation, reactive oxygen species generation, inflammatory cytokine production, and antimicrobial signaling. ACE-iNeu exhibited enhanced bactericidal activity against methicillin-resistant Staphylococcus aureus and multidrug-resistant Pseudomonas aeruginosa. Following adoptive transfer into neutropenic mice, ACE-iNeu significantly reduced circulating and tissue bacterial burdens. Integrated metabolomic and transcriptomic analyses revealed ACE-associated alterations in adenine nucleotide abundance and developmental and inflammatory pathways. Together, these findings establish ACE engineering as a strategy to enhance the production and antimicrobial function of human iPSC-derived neutrophils and support further preclinical development of engineered granulocyte therapies for severe drug-resistant infections.

immunology↗

Tetravalent dengue mRNA vaccination orchestrates balanced four-serotype immunity with durable memory and protection in mice.

An effective dengue vaccine must establish durable immunity across four dengue virus (DENV) serotypes, evade antibody-dependent enhancement (ADE), and overcome immune imprinting from prior exposure. Here, we developed TetprM-E mRNA-LNP, a tetravalent vaccine comprising LNP-formulated nucleoside-modified mRNAs encoding DENV1-4 precursor membrane-envelope (prM-E) antigens, and evaluated its immunogenicity, durability, protection and breath across serotype-specific immune backgrounds. Three immunization strategies elicited neutralizing titers greater than 1:1500 against each serotype. Passive transfer of immune sera conferred 100% survival and reduced viremia after lethal DENV2 challenge in immunocompromised mice. Vaccination induced DENV envelope (env)-specific CD8+T cells and CD4-dependent germinal-center responses. DENV env-binding antibodies persisted for 34 weeks alongside DENV env-specific memory B cells. Vaccine-elicited sera showed no measurable in vitro ADE. Although monovalent priming initially biased antibody responses, TetprM-E mRNA-LNP vaccination broadened neutralization across DENV1-4 regardless of priming serotype. Together, TetprM-E mRNA-LNP elicits broad, durable, and protective immunity despite serologic constraints from pre-existing immunity.

immunology↗